Loading...

Brilliant Violet 510™ anti-mouse CD4 Antibody

Pricing & Availability
Clone
RM4-5 (See other available formats)
Regulatory Status
RUO
Other Names
L3T4, T4
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
RM4-5_BV510_CD4_Antibody_FC_082312
C57BL/6 mouse splenocytes were stained with CD3 APC and CD4 (clone RM4-5) Brilliant Violet 510™.
  • RM4-5_BV510_CD4_Antibody_FC_082312
    C57BL/6 mouse splenocytes were stained with CD3 APC and CD4 (clone RM4-5) Brilliant Violet 510™.
Compare all formats See Brilliant Violet 510™ spectral data
Cat # Size Price Quantity Check Availability Save
100553 125 µL £117
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100559 50 µg £166
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD4 is a 55 kD protein also known as L3T4 or T4. It is a member of the Ig superfamily, primarily expressed on most thymocytes and a subset of T cells, and weakly on macrophages and dendritic cells. It acts as a co-receptor with the TCR during T cell activation and thymic differentiation by binding MHC class II and associating with the protein tyrosine kinase lck.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
BALB/c mouse thymocytes
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation
The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 510™ under optimal conditions.
Concentration
µg sizes: 0.2 mg/mL
µL sizes: lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For immunofluorescent staining using the µg size, the suggested use of this reagent is ≤0.5 µg per million cells in 100 µl volume. For immunofluorescent staining using the µl size, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 510™ excites at 405 nm and emits at 510 nm. The bandpass filter 510/50 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 510™ is a trademark of Sirigen Group Ltd.


Learn more about Brilliant Violet™.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser
Violet Laser (405 nm)
Application Notes

The RM4-5 antibody blocks the binding of GK1.5 antibody and H129.19 antibody to CD4+ T cells, but not RM4-4 antibody. Additional reported applications (for the relevant formats) include: blocking of ligand binding, in vivo depletion of CD4+ cells1, and immunohistochemistry of acetone-fixed frozen tissue sections2,3,11 and paraffin-embedded sections11. Clone RM4-5 is not recommended for immunohistochemistry of formalin-fixed paraffin sections. Instead, acetone frozen or zinc-fixed paraffin sections are recommended. The Ultra-LEAF™ Purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 100575 and 100576).

Application References

(PubMed link indicates BioLegend citation)
  1. Kruisbeek AM. 1991. In Curr. Protocols Immunol. pp. 4.1.1-4.1.5. (Block, Deplete)
  2. Nitta H, et al. 1997. Cell Vision 4:73. (IHC)
  3. Fan WY, et al. 2001. Exp. Biol. Med. 226:1045.
  4. Muraille E, et al. 2003. Infect. Immun. 71:2704. (IHC)
  5. León-Ponte M, et al. 2007. Blood 109:3139. (FC)
  6. Bourdeau A, et al. 2007. Blood doi:10.1182/blood-2006-08-044370. (FC)
  7. Matsumoto M, et al. 2007.J. Immunol.178:2499. PubMed
  8. Shigeta A, et al. 2008. Blood 112:4915. PubMed
  9. Zaborsky N, et al. 2010. J. Immunol. 184:725. PubMed
  10. Rodrigues-Manzanet R, et al. 2010. P. Natl Acad Sci USA 107:8706. PubMed
  11. Whiteland JL, et al. 1995. J. Histochem. Cytochem. 43:313. (IHC)
Product Citations
  1. Apte SH, et al. 2020. Clin Transl Immunology. 9:e1209. PubMed
  2. Koenig A, et al. 2022. Front Immunol. 12:791100. PubMed
  3. Weng S, et al. 2022. Front Immunol. 13:1025931. PubMed
  4. Zhu X, et al. 2023. Front Immunol. 14:1114802. PubMed
  5. Gon Y, et al. 2023. PLoS One. 18:e0279389. PubMed
  6. Dvorscek AR, et al. 2022. EMBO Rep. 23:e54677. PubMed
  7. Wu Z, et al. 2023. EMBO Rep. 24:e56524. PubMed
  8. Tursi NJ, et al. 2023. Front Immunol. 14:1072810. PubMed
  9. Yazicioglu YF, et al. 2023. Nat Immunol. 24:991. PubMed
  10. Dijkman K, et al. 2023. NPJ Vaccines. 8:66. PubMed
  11. Miragaia RJ, et al. 2019. Immunity. 50:493. PubMed
  12. Shibata K, et al. 2022. Nat Commun. 13:6948. PubMed
  13. Wilfahrt D, et al. 2021. Elife. 10:. PubMed
  14. Gern BH, et al. 2021. Cell Host Microbe. 29(4):594-606.e6. PubMed
  15. Wang L, et al. 2019. Cell Rep. 29:1848. PubMed
  16. Baram T, et al. 2021. Cells. 10:. PubMed
  17. Piepke M, et al. 2021. J Neuroinflammation. 18:265. PubMed
  18. Hu W, et al. 2021. Nat Immunol. 22:1163. PubMed
  19. Wang D, et al. 2018. Immunity. 48:659. PubMed
  20. Lancaster JN, et al. 2019. Nat Commun. 10:2220. PubMed
  21. Clemmensen HS, et al. 2021. MBio. 12:. PubMed
  22. Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed
  23. Plumlee CR, et al. 2020. Cell Host Microbe. 29(1):68-82.e5. PubMed
  24. Konrath KM, et al. 2022. Cell Rep. 38:110318. PubMed
  25. Neubert K, et al. 2014. J Immunol. 192:5830. PubMed
  26. Zhu B, et al. 2021. Immunity. 54(6):1200-1218.e9. PubMed
  27. Woodworth JS, et al. 2021. Nat Commun. 12:6658. PubMed
  28. Marangoni F, et al. 2021. Cell. . PubMed
  29. Latif AL, et al. 2021. Nat Commun. 0.667361111. PubMed
  30. Blankenhaus B, et al. 2014. PLoS Pathog. 10:1003913. PubMed
  31. Lee JY, et al. 2020. Cell. 180(1):79-91.e16.. PubMed
  32. Liu YJ, et al. 2020. Theranostics. 10:5225. PubMed
  33. Zirngibl F, et al. 2021. J Immunother Cancer. 9:. PubMed
  34. Clemmensen HS, et al. 2020. Front Immunol. 11:585359. PubMed
  35. Dikiy S, et al. 2021. Immunity. 54(5):931-946.e11. PubMed
  36. Stump CT, et al. 2021. Open Biol. 11:210245. PubMed
  37. Kawakami R, et al. 2021. Immunity. 54(5):947-961.e8. PubMed
  38. Teixeira L, et al. 2016. Sci Rep. 6:23475. PubMed
  39. Grzelak A, et al. 2018. Int J Mol Sci. 19:. PubMed
  40. Xu Z, et al. 2020. Cancer Immunol Res. 1354:8. PubMed
  41. Lima-Junior DS, et al. 2021. Cell. . PubMed
  42. Kaur A, et al. 2019. Cancer Discov. 9:64. PubMed
  43. Galle-Treger L, et al. 2016. Nat Commun. 7:13202. PubMed
  44. Liu Z, et al. 2020. Cell. 178(6):1509-1525.e19.. PubMed
  45. Fu Y, et al. 2021. Front Cell Dev Biol. 9:689727. PubMed
  46. Jandke A, et al. 2020. Nat Commun. 3.075694444. PubMed
  47. Stacy A, et al. 2021. Cell. 184(3):615-627.e17. PubMed
  48. Echevarría-Vargas IM, et al. 2018. EMBO Mol Med. 10:e8446. PubMed
  49. Kim DK, et al. 2022. Nat Commun. 13:6292. PubMed
  50. Kwok T, et al. 2022. Front Aging. 3:838943. PubMed
  51. Lofano G, et al. 2015. J Immunol. 195: 1617-1627. PubMed
  52. Renoux F, et al. 2020. Cell Reports. 31(13):107826. PubMed
  53. Phalke SP, et al. 2019. PLoS One. 14:e0218827. PubMed
  54. Revathikumar P, et al. 2018. PLoS One. 13:e0193210. PubMed
  55. Jiang L, et al. 2020. Cell. 183(5):1219-1233.e18. PubMed
  56. Blanchfield L,et al. 2017. J Immunol. 10.4049/jimmunol.1700792. PubMed
  57. Filskov J, et al. 2019. Sci Rep. 9:14085. PubMed
  58. Renner K, et al. 2020. Cell Reports. 29(1):135-150.e9.. PubMed
  59. Hoyer FF, et al. 2020. Immunity. 51(5):899-914.e7.. PubMed
  60. Xiao Z, et al. 2022. Mater Today Bio. 15:100297. PubMed
  61. Seo GY et al. 2018. Cell host & microbe. 24(2):249-260 . PubMed
  62. Alterauge D, et al. 2020. Cell Rep. 33:108232. PubMed
  63. Dammeijer F, et al. 2020. Cancer Cell. 38(5):685-700.e8. PubMed
  64. Reinke S, et al. 2020. Cell Reports. 30(8):2501-2511. PubMed
RRID
AB_2561388 (BioLegend Cat. No. 100553)
AB_2561388 (BioLegend Cat. No. 100559)

Antigen Details

Structure
Ig superfamily, 55 kD
Distribution

Majority of thymocytes, T cell subset

Function
TCR co-receptor, T cell activation
Ligand/Receptor
MHC class II molecule
Cell Type
Dendritic cells, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Bierer BE, et al. 1989. Annu. Rev. Immunol. 7:579.
3. Janeway CA. 1992. Annu. Rev. Immunol. 10:645.

Gene ID
12504 View all products for this Gene ID
UniProt
View information about CD4 on UniProt.org

Related FAQs

I am unable to see expression of T cell markers such as CD3 and CD4 post activation.
TCR-CD3 complexes on the T-lymphocyte surface are rapidly downregulated upon activation with peptide-MHC complex, superantigen or cross-linking with anti-TCR or anti-CD3 antibodies. PMA/Ionomycin treatment has been shown to downregulate surface CD4 expression. Receptor downregulation is a common biological phenomenon and so make sure that your stimulation treatment is not causing it in your sample type.
Go To Top Version: 2    Revision Date: 01/29/2013

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account